abstract |
The present disclosure relates to pharmaceutical compositions and methods for treating diseases or conditions associated with insufficient opening of Cx43 half-channels in osteocytes, preferably for treating cancer, cancer metastasis, osteosarcoma, osteoporosis, or osteopenia. |